|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US20020142000A1
(en)
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
ATE323366T1
(de)
|
2000-10-05 |
2006-04-15 |
Matsushita Electric Industrial Co Ltd |
Initialisierungsverfahren und datensender
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US20020165360A1
(en)
|
2000-11-30 |
2002-11-07 |
Junghans Richard P. |
Chimeric effector cell receptors against carcinoembryonic antigen
|
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
CA2471551C
(en)
|
2001-12-27 |
2014-09-30 |
Glycofi, Inc. |
Methods to engineer mammalian-type carbohydrate structures
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
KR20050000380A
(ko)
|
2002-04-09 |
2005-01-03 |
교와 핫꼬 고교 가부시끼가이샤 |
게놈이 개변된 세포
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
WO2003084570A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
|
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
|
WO2003085102A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7232888B2
(en)
|
2002-07-01 |
2007-06-19 |
Massachusetts Institute Of Technology |
Antibodies against tumor surface antigens
|
|
EP1539966B1
(en)
|
2002-09-12 |
2010-06-30 |
Greenovation Biotech GmbH |
Protein production method
|
|
AU2003294912B2
(en)
|
2002-12-20 |
2009-06-04 |
Greenovation Biotech Gmbh |
Production of heterologous glycosylated proteins in bryophyte cells
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
KR101498588B1
(ko)
|
2003-01-22 |
2015-03-05 |
로슈 글리카트 아게 |
융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
|
|
WO2005018669A1
(en)
|
2003-08-18 |
2005-03-03 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
AU2005277641A1
(en)
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
AU2006230413B8
(en)
|
2005-03-31 |
2011-01-20 |
Xencor, Inc |
Fc variants with optimized properties
|
|
CA2606102C
(en)
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗ｃｄ３０抗体
|
|
US8236308B2
(en)
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
ES2642787T3
(es)
|
2005-10-21 |
2017-11-20 |
Lfb Usa, Inc. |
Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
|
|
NZ569204A
(en)
|
2005-12-21 |
2012-03-30 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
|
|
JP2009529331A
(ja)
|
2006-03-10 |
2009-08-20 |
マクロジェニクス，インコーポレーテッド |
変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
|
|
IL177158A0
(en)
|
2006-07-30 |
2008-01-20 |
Assaf Klar |
Method for designing and implementing improved longitudinal flexibility multilayered pipeline
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
EP2064240A2
(en)
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
WO2008091798A2
(en)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
|
CA2669412A1
(en)
|
2007-01-23 |
2008-07-31 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
WO2008098115A2
(en)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
PL2155788T3
(pl)
|
2007-04-03 |
2013-02-28 |
Amgen Res Munich Gmbh |
Swoiste międzygatunkowe bispecyficzne czynniki wiążące
|
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
PL2282773T3
(pl)
|
2008-05-02 |
2014-08-29 |
Seattle Genetics Inc |
Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
PT3190128T
(pt)
|
2008-09-17 |
2019-02-07 |
Xencor Inc |
Composições e métodos para tratar distúrbios mediados pela ige
|
|
MX2011003502A
(es)
|
2008-10-01 |
2011-09-01 |
Micromet Ag |
Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
|
|
EP2352763B2
(en)
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
WO2011034660A1
(en)
|
2009-09-16 |
2011-03-24 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
WO2012023053A2
(en)
|
2010-08-16 |
2012-02-23 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
|
KR101981342B1
(ko)
|
2011-03-02 |
2019-05-22 |
로슈 글리카트 아게 |
Cea 항체
|
|
US20140242081A1
(en)
|
2011-07-18 |
2014-08-28 |
Micromet Ag |
Dosing regimens for treatment of cea-expressing cancers
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
ES2767135T3
(es)
|
2011-10-19 |
2020-06-16 |
Novimmune Sa |
Métodos para purificar anticuerpos
|
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
PT3199552T
(pt)
|
2012-11-20 |
2020-03-25 |
Sanofi Sa |
Anticorpos anti-ceacam5 e suas utilizações
|
|
RU2693078C2
(ru)
|
2012-12-03 |
2019-07-01 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN110437337B
(zh)
|
2013-02-26 |
2024-07-30 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
WO2014179132A1
(en)
|
2013-04-29 |
2014-11-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of anti-cd47 agents to enhance immunization
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
US11046763B2
(en)
|
2014-01-08 |
2021-06-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted therapy for small cell lung cancer
|
|
WO2015112534A2
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
CN106604933B
(zh)
|
2014-07-11 |
2021-08-10 |
文塔纳医疗系统公司 |
抗pd-l1抗体及其诊断用途
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
TWI595006B
(zh)
*
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
EP3261678B8
(en)
|
2015-01-23 |
2021-03-17 |
Helix Biopharma Corp. |
Antibody-urease conjugates for therapeutic purposes
|
|
JP6815329B2
(ja)
*
|
2015-03-23 |
2021-01-20 |
バイエル ファーマ アクチエンゲゼルシャフト |
抗ｃｅａｃａｍ６抗体およびその使用
|
|
ES2752054T3
(es)
|
2015-03-31 |
2020-04-02 |
Novimmune Sa |
Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas
|
|
DE102015212888A1
(de)
|
2015-07-09 |
2017-01-12 |
BSH Hausgeräte GmbH |
Geschirrspülmaschine mit einer Trocknungseinrichtung
|
|
RU2740672C2
(ru)
*
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
|
|
EP3165536A1
(en)
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
|
GB2546072B
(en)
|
2016-01-05 |
2019-07-10 |
Bja Trading Ltd |
Attachment assembly and method of using same
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
CA3011097C
(en)
*
|
2016-01-11 |
2022-12-20 |
Forty Seven, Inc. |
Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
|
|
WO2017196793A1
(en)
|
2016-05-09 |
2017-11-16 |
Celgene Corporation |
Cd47 antibodies and methods of use thereof
|
|
CN107556386A
(zh)
*
|
2016-06-30 |
2018-01-09 |
中国科学院深圳先进技术研究院 |
抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
|
|
GB201611530D0
(en)
*
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
WO2018098384A1
(en)
*
|
2016-11-22 |
2018-05-31 |
Regents Of The University Of California |
Segregation modulation for immunotherapy
|
|
CN112566938B
(zh)
|
2018-06-03 |
2025-04-01 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
|
KR20230121772A
(ko)
*
|
2020-12-18 |
2023-08-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체
|